Spero Therapeutics raises $105m royalty financing to fund SP001 Phase 2
Spero Therapeutics has secured $105 million in non-dilutive financing through a royalty monetisation agreement with Healthcare Royalty (HCRx), a business majority-owned by KKR. Under the deal, HCRx will receive a portion of future milestone and royalty payments tied to sales of Utebzi (tebipenem pivoxil), Spero's recently approved oral carbapenem antibiotic, in exchange for the upfront capital. Proceeds will primarily fund Phase 2 development of SP001, Spero's lead immunology candidate, which was in-licensed from Innovent Biologics concurrently with the financing closing.
The transaction extends Spero's cash runway guidance into the second half of 2029, a meaningful extension for a company executing a pivot from anti-infectives into immunology. Following full repayment of the loan principal and interest, Spero retains 35% of subsequent GSK payments related to Utebzi sales, preserving long-term commercial upside. GSK holds an exclusive licence to develop and commercialise Utebzi across most territories; Meiji holds rights in certain parts of Asia.
The asset: SP001 and the CD40L mechanism
SP001 is a third-generation, fully humanised, Fc-silent IgG1 monoclonal antibody targeting CD40L, a co-stimulatory molecule involved in the activation of T cells, B cells, antigen-presenting cells, and platelets. The CD40L pathway has long attracted drug developers because of its upstream role in chronic inflammatory and autoimmune conditions, but earlier anti-CD40L antibodies were associated with thromboembolic events linked to platelet activation. Spero says the Fc-silent engineering in SP001 is designed to address that concern while preserving FcRn interaction and IgG-like half-life, making it more viable for chronic dosing. The company is advancing SP001 first in IgG4-related disease, a fibroinflammatory condition with limited approved options, and has described broader ambitions across immune-mediated diseases.
Esther Rajavelu, President and Chief Executive Officer of Spero Therapeutics, said the deal "further strengthens our balance sheet and provides non-dilutive capital as we embark on an immunology-focused strategy," adding that unlocking value from Utebzi's royalty stream allows the company to pursue SP001's clinical development without shareholder dilution.
Market context and competitive landscape
The anti-CD40L space has historically been difficult, with earlier programmes shelved after safety concerns. However, renewed engineering approaches have attracted several biotechs back to the target, and the regulatory environment for rare autoimmune conditions such as IgG4-related disease has become more defined, with FDA granting breakthrough designations in adjacent indications. Spero's Fc-silent approach places it in a cohort of developers attempting to rehabilitate the mechanism through molecular redesign.
Royalty monetisation as a financing tool has grown considerably in the life sciences sector, with firms such as Royalty Pharma, PDL BioPharma's successors, and HCRx itself becoming significant providers of non-dilutive capital. For a company with Spero's market capitalisation, trading on Nasdaq under the ticker SPRO, the structure avoids equity issuance at what may be a depressed share price while still accessing meaningful capital. The key risk is that future Utebzi commercial performance, which flows through GSK's commercialisation efforts, will determine how quickly the loan is repaid and how much residual royalty Spero ultimately collects. The first approved oral carbapenem carries genuine clinical novelty, but uptake in complicated urinary tract infections will depend on antimicrobial stewardship dynamics and payer acceptance.